Top

Published in:

01-07-2013 | Translational Neurosciences - Original Article

Impact of subcortical white matter lesions on dopamine transporter SPECT

Authors: Elisabeth Funke, Andreas Kupsch, Ralph Buchert, Winfried Brenner, Michail Plotkin

Published in: Journal of Neural Transmission | Issue 7/2013

Abstract

Subcortical arteriosclerotic encephalopathy (SAE) can affect the nigrostriatal system and presumably cause vascular parkinsonism (VP). However, in patients with SAE, the differentiation of VP from idiopathic Parkinson’s disease (IPS) is challenging. The aim of the present study was to examine the striatal dopamine transporter (DAT) density in patients with parkinsonism and SAE. Fifteen consecutive patients with parkinsonian symptoms displayed SAE, as detected by magnetic resonance imaging (MRI). Fifteen retrospectively chosen, matched patients with diagnosis of IPS without any abnormalities in MRI served as a reference group. DAT SPECT was performed using the tracer ¹²³I-FP-CIT. Scans were acquired on a triple-head SPECT system (Multispect 3, Siemens) and analysed using the investigator-independent BRASS™ software (HERMES). In the SAE group, a DAT deficit was observed in 9/15 patients. In contrast, all patients from the IPS group showed a reduced DAT binding (p = 0.008). The specific binding ratios (BR) of putamen contralateral to the side of the more affected limb versus occipital lobe were in trend higher in patients with SAE versus patients in the IPS-group (p = 0.053). Indices for putaminal asymmetry (p = 0.036) and asymmetry caudate-to-putamen (p = 0.026) as well as the ratio caudate-to-putamen (p = 0.048) were significantly higher in IPS patients having no SAE. DAT deficit was less pronounced in patients with SAE and parkinsonism than in patients with IPS without any abnormalities in the MRI. A potential role of DAT SPECT in the differential diagnosis of VP and IPS requires more assessments within prospective studies.

Antonini A, Vitale C, Barone P et al (2012) The relationship between cerebral vascular disease and parkinsonism: the VADO study. Parkinsonism Relat Disord 18(6):775–780PubMedCrossRef

Bain PG (2009) Dystonic tremor presenting as parkinsonism: long-term follow-up of SWEDDs. Neurology 72(16):1443–1445PubMedCrossRef

Boecker H, Weindl A, Leenders K et al (1996) Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. Acta Neurol Scand 93(6):387–392PubMedCrossRef

Bohnen NI, Albin RL (2011) White matter lesions in Parkinson disease. Nat Rev Neurol 7(4):229–236PubMedCrossRef

Bower JH, Maraganore DM, McDonnell SK et al (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 52(6):1214–1220PubMedCrossRef

Brucke T, Asenbaum S, Pirker W et al (1997) Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50:9–24PubMedCrossRef

Chang CM, Yu YL, Ng HK et al (1992) Vascular pseudoparkinsonism. Acta Neurol Scand 86(6):588–592PubMedCrossRef

Critchley M (1929) Arteriosclerotic Parkinsonism. Brain 52(1):23–83CrossRef

de Rijk MC, Tzourio C, Breteler MM et al (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 62(1):10–15PubMedCrossRef

Demirkiran M, Bozdemir H, Sarica Y (2001) Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand 104(2):63–67PubMedCrossRef

Ebersbach G, Poewe W (2006) Vascular parkinsonian syndrome. Nervenarzt 77(2):139–144, 146–137

Fahn S (2006) A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl 70:419–426PubMedCrossRef

Foltynie T, Barker R, Brayne C (2002) Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology 21(1):1–7PubMedCrossRef

Gerschlager W, Bencsits G, Pirker W et al (2002) [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov Disord 17(3):518–523PubMedCrossRef

Ghebremedhin E, Rosenberger A, Rub U et al (2010) Inverse relationship between cerebrovascular lesions and severity of Lewy body pathology in patients with Lewy body diseases. J Neuropathol Exp Neurol 69(5):442–448PubMedCrossRef

Hesse S, Oehlwein C, Barthel H et al (2006) Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm 113(9):1177–1190PubMedCrossRef

Hughes AJ, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184PubMedCrossRef

Kalra S, Grosset DG, Benamer HT (2010) Differentiating vascular parkinsonism from idiopathic Parkinson’s disease: a systematic review. Mov Disord 25(2):149–156PubMedCrossRef

Lorberboym M, Djaldetti R, Melamed E et al (2004) 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 45(10):1688–1693PubMed

Marek KL, Seibyl JP, Zoghbi SS et al (1996) [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46(1):231–237PubMedCrossRef

Marek K, Jennings D, Seibyl J (2003) Dopamine agonists and Parkinson’s disease progression: what can we learn from neuroimaging studies. Ann Neurol 53(Suppl 3):S160–S166 (discussion S166–S169)PubMedCrossRef

Mark MH, Sage JI, Walters AS et al (1995) Binswanger’s disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases. Mov Disord 10(4):450–454PubMedCrossRef

Nakane M, Teraoka A, Asato R et al (1992) Degeneration of the ipsilateral substantia nigra following cerebral infarction in the striatum. Stroke 23(3):328–332PubMedCrossRef

Nakayama H, Tamura A, Kanazawa I et al (1990) Time-sequential change of amino acid neurotransmitters—GABA, aspartate and glutamate—in the rat basal ganglia following middle cerebral artery occlusion. Neurol Res 12(4):231–235PubMed

Peralta C, Werner P, Holl B et al (2004) Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. J Neural Transm 111(10–11):1473–1483PubMedCrossRef

Piccini P, Pavese N, Canapicchi R et al (1995) White matter hyperintensities in Parkinson’s disease. Clinical correlations. Arch Neurol 52(2):191–194PubMedCrossRef

Plotkin M, Amthauer H, Klaffke S et al (2005a) Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 112(5):677–692PubMedCrossRef

Plotkin M, Amthauer H, Quill S et al (2005b) Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases. J Neural Transm 112(10):1355–1361PubMedCrossRef

Reitz C, Trenkwalder C, Kretzschmar K et al (2006) Relation of cerebral small-vessel disease and brain atrophy to mild Parkinsonism in the elderly. Mov Disord 21(11):1914–1919PubMedCrossRef

Santangelo G, Vitale C, Trojano L et al (2010) Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. Mov Disord 25(1):50–56PubMedCrossRef

Seibyl JP, Marek KL, Quinlan D et al (1995) Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 38(4):589–598PubMedCrossRef

Sixel-Doring F, Liepe K, Mollenhauer B et al (2011) The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol 258(12):2147–2154PubMedCrossRef

Thanvi B, Lo N, Robinson T (2005) Vascular parkinsonism—an important cause of parkinsonism in older people. Age Ageing 34(2):114–119PubMedCrossRef

Thompson PD, Marsden CD (1987) Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger’s disease. Mov Disord 2(1):1–8PubMedCrossRef

Tohgi H, Takahashi S, Abe T et al (2001) Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism. Eur Neurol 46(1):1–10PubMedCrossRef

Trenkwalder C, Schwarz J, Gebhard J et al (1995) Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 52(10):1017–1022PubMedCrossRef

Tzen KY, Lu CS, Yen TC et al (2001) Differential diagnosis of Parkinson’s disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med 42(3):408–413PubMed

van Zagten M, Lodder J, Kessels F (1998) Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov Disord 13(1):89–95PubMedCrossRef

Vlaar AM, de Nijs T, Kessels AG et al (2008) Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 59(5):258–266PubMedCrossRef

Whone AL, Watts RL, Stoessl AJ et al (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54(1):93–101PubMedCrossRef

Winikates J, Jankovic J (1999) Clinical correlates of vascular parkinsonism. Arch Neurol 56(1):98–102PubMedCrossRef

Zijlmans JC (2010) The role of imaging in the diagnosis of vascular parkinsonism. Neuroimaging Clin N Am 20(1):69–76PubMedCrossRef

Zijlmans JC, Thijssen HO, Vogels OJ et al (1995) MRI in patients with suspected vascular parkinsonism. Neurology 45(12):2183–2188PubMedCrossRef

Zijlmans JC, Daniel SE, Hughes AJ et al (2004) Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 19(6):630–640PubMedCrossRef

Zijlmans J, Evans A, Fontes F et al (2007) [123I] FP-CIT spect study in vascular parkinsonism and Parkinson’s disease. Mov Disord 22(9):1278–1285PubMedCrossRef

Title: Impact of subcortical white matter lesions on dopamine transporter SPECT
Authors: Elisabeth Funke
Andreas Kupsch
Ralph Buchert
Winfried Brenner
Michail Plotkin
Publication date: 01-07-2013
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 7/2013
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-013-0977-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of subcortical white matter lesions on dopamine transporter SPECT

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

Attention in essential tremor: evidence from event-related potentials

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER

Effects of leptin on pedunculopontine nucleus (PPN) neurons

Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children

Theta responses are abnormal in mild cognitive impairment: evidence from analysis of theta event-related synchronization during a temporal expectancy task

Abstracts of the Second International Congress on Treatment of Dystonia together with the First International Congress on Rehabilitation of Dystonia May 8–11, 2013 Hannover, Germany